UBS Initiates Coverage of ShockWave Medical Inc
January 4, 2024
🌥️Trending News
SHOCKWAVE ($NASDAQ:SWAV): UBS – KNOX Daily has initiated a rating for ShockWave Medical Inc, a medical technology company based in the US. The company creates and develops interventional products that use ultrasound and shockwave technology to treat common cardiovascular and renal diseases. The ShockWave System is designed to provide minimally-invasive treatments which offer physicians and patients tailored solutions. UBS’s rating for ShockWave Medical Inc is backed by a strong track record of how the company has performed in the last year and its outlook for future growth. With a portfolio of products that are leaders in their respective markets, the company has achieved impressive sales through strategic partnerships and distribution channel expansion.
In addition, the company’s investments in research and development have continued to develop breakthrough treatments that offer patients improved outcomes with minimal side effects. The company also has a strong financial position and is well-positioned to be able to capitalize on new opportunities as they arise.
Additionally, the experienced leadership team has been able to create long-term value for shareholders and build a successful business strategy. UBS’s rating for ShockWave Medical Inc reflects the company’s strong financial position, market leadership, and commitment to innovation. With its impressive track record, strong financials, and innovative products, ShockWave Medical Inc is an attractive investment opportunity for investors looking for long-term growth prospects.
Stock Price
UBS recently initiated coverage of ShockWave Medical Inc, a publicly traded medical technology company. On Tuesday, the stock of SHOCKWAVE MEDICAL opened at $187.4 and closed at $194.6, up 2.1% from its last closing price of $190.6. This positive performance may be attributed to the company’s innovative technologies, which are revolutionizing the medical industry with its targeted therapies for both calcified and non-calcified vascular disease.
Additionally, SHOCKWAVE MEDICAL’s products have also been successful in treating peripheral artery disease, coronary artery disease, and renal denervation. The company’s commitment to innovation and development of new technologies suggests that future growth is likely, making SHOCKWAVE MEDICAL an attractive investment option for investors. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Shockwave Medical. More…
| Total Revenues | Net Income | Net Margin |
| 671.28 | 243.88 | 36.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Shockwave Medical. More…
| Operations | Investing | Financing |
| 176.79 | -418.74 | 610.16 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Shockwave Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.47k | 872.71 | 16.3 |
Key Ratios Snapshot
Some of the financial key ratios for Shockwave Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 124.4% | – | 25.1% |
| FCF Margin | ROE | ROA |
| 21.3% | 17.3% | 7.1% |
Analysis
At GoodWhale, we analyzed the fundamentals of SHOCKWAVE MEDICAL to evaluate its potential as an investment. Our Star Chart shows that SHOCKWAVE MEDICAL is strong in assets, growth, and profitability, but weak in dividend. We classified this company as a ‘gorilla’, which is a type of company that has achieved stable and high revenue or earning growth due to its strong competitive advantage. We believe that SHOCKWAVE MEDICAL is an attractive investment for investors looking for long-term growth. With an intermediate health score of 6/10 with regard to its cashflows and debt, SHOCKWAVE MEDICAL might be able to safely ride out any crisis without the risk of bankruptcy. For investors looking for high returns, SHOCKWAVE MEDICAL is an excellent choice. More…
Peers
The medical device industry is an ever-evolving landscape, with many companies competing to develop the most impactful and innovative solutions. One of the major players in this field is ShockWave Medical Inc, which has recently been engaged in a fierce competition with other notable players such as Inspire Medical Systems Inc, Inari Medical Inc, and INVO Bioscience Inc. Each of these companies has their own unique approach to developing cutting-edge medical technology, and their competition is driving innovation and progress in the industry.
– Inspire Medical Systems Inc ($NYSE:INSP)
Inspire Medical Systems Inc is a medical device company that specializes in the development of minimally invasive solutions for treating obstructive sleep apnea (OSA). The company has a market capitalization of 6.71 billion US dollars as of 2022, making it one of the larger companies in its sector. The company’s Return on Equity (ROE) is -8.55%, which suggests that the company is not generating a positive return on its shareholders’ investments. This is likely due to the high costs associated with R&D and clinical trials associated with developing new products and treatments. Despite this, Inspire Medical Systems Inc remains a leader in its sector, having developed innovative solutions that are helping to improve the lives of patients around the world.
– Inari Medical Inc ($NASDAQ:NARI)
Inari Medical Inc is a medical technology company that develops innovative medical devices for treating vascular diseases. The company has a market cap of 3.67 billion USD as of 2022, indicating a strong market presence and demonstrating that investors are confident in the company’s long-term prospects. Additionally, Inari Medical Inc has a return on equity of -2.93%, which suggests that the company has not been able to generate profits from its investments. This could be due to the company’s investments into research and development, as well as its expensive start-up costs.
– INVO Bioscience Inc ($NASDAQ:INVO)
INVO Bioscience Inc is a medical device company that focuses on developing and commercializing innovative products for the treatment of infertility. The company has a market cap of 7.3M as of 2022, indicating that its current market value is relatively small compared to its competitors. Its Return on Equity of -210.86% shows that the company is not performing well, as it has been burning through cash and not generating sufficient returns on its investments.
Summary
UBS has given ShockWave Medical Inc an Initiated rating, indicating a positive outlook on the company’s potential as an investment. UBS analysts suggest that ShockWave Medical Inc is in a strong position due to its innovative product offerings and growing customer base. The company is already seeing strong sales growth with increasing gross and net margins, and is well-positioned to benefit from the growing demand for medical technology.
In addition, ShockWave Medical Inc has a sound balance sheet and favorable debt-to-equity ratio. UBS believes ShockWave Medical Inc is a good long-term investment opportunity and recommends investors consider it for their portfolios.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
